Variability in 4-hydroperoxycyclophosphamide activity during clinical purging for autologous bone marrow transplantation

R. J. Jones, M. Zuehlsdorf, S. D. Rowley, J. Hilton, G. W. Santos, L. L. Sensenbrenner, M. O. Colvin

Research output: Contribution to journalArticle

Abstract

We examined the effects of varying incubation conditions on the in vitro activity of 4-hydroperoxycyclophosphamide (4HC). 4HC activity against CFU-GM and against the K562 tumor cell line decreased with increasing the RBC concentration of the incubation mixture. Increasing the concentration of nucleated bone marrow cells in the incubation mixture also decreased the 4HC activity. Evaluation of 53 consecutive patients undergoing autologus bone marrow transplantation (BMT) revealed that the incubation RBC concentration during clinical purging showed a similar effect on CFU-GM recovery. Aldehyde dehydrogenase content of RBCs and nucleated marrow cells appears to be the cause of the inhibition of 4HC activity. Although there was no difference in individual CFU-GM sensitivity to 4HC among normals, previously treated patients undergoing autologous BMT showed significant variability in CFU-GM sensitivity to 4HC. The combined effects of incubation RBC concentration and individual patient 4HC sensitivity appear to account for most of the variability in CFU-GM recovery and speed of hematologic recovery after clinical purging with 4HC.

Original languageEnglish (US)
Pages (from-to)1490-1494
Number of pages5
JournalBlood
Volume70
Issue number5
StatePublished - Dec 1 1987

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Fingerprint Dive into the research topics of 'Variability in 4-hydroperoxycyclophosphamide activity during clinical purging for autologous bone marrow transplantation'. Together they form a unique fingerprint.

  • Cite this

    Jones, R. J., Zuehlsdorf, M., Rowley, S. D., Hilton, J., Santos, G. W., Sensenbrenner, L. L., & Colvin, M. O. (1987). Variability in 4-hydroperoxycyclophosphamide activity during clinical purging for autologous bone marrow transplantation. Blood, 70(5), 1490-1494.